News | April 11, 2021
NATCO receives approval for Ibrutinib tablets from ANDA
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The government has taken all the effective measures to make healthcare affordable
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
India produces 60% of the world’s vaccine
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The vaccine was 85 percent effective in preventing severe disease across all regions.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Subscribe To Our Newsletter & Stay Updated
